1. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan 
Jesse H. Morris, Nicole M. Bohm, Branden D. Nemecek, Rachel Crawford, Denise Kelley, Bhavna Bhasin, Paul J. Nietert, Juan Carlos Q. Velez 
American Journal of Kidney Diseases 
Volume 71, Issue 6, Pages (June 2018)
DOI: /j.ajkd
Copyright © 2018 National Kidney Foundation, Inc. Terms and Conditions

2. Figure 1
Flow chart illustrates the stepwise process followed for the selection of cases for inclusion in the study. Abbreviations: CHF, congestive heart failure; IV, intravenous; SIADH, syndrome of inappropriate secretion of antidiuretic hormone; sNa, serum sodium.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2018 National Kidney Foundation, Inc. Terms and Conditions

3. Figure 2
(A) Trajectories depict change in serum sodium concentration during the initial 24-hour period following tolvaptan administration in the syndrome of inappropriate secretion of antidiuretic hormone (SIADH; black) and congestive heart failure (CHF; gray) cohorts. Dashed curves show trends based on the linear mixed-effects model adjusted predicted means in serum sodium measurements, whereas circular data markers show unadjusted mean values at each time point. Size of the marker is proportional to the sample size at each time point. ¥P< between slopes. (B) Treatment safety (unadjusted rates of rapid hyponatremia correction based on 2 alternate definitions) and treatment efficacy in the SIADH and CHF cohorts. ∗P<0.001.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2018 National Kidney Foundation, Inc. Terms and Conditions

4. Figure 3
Unadjusted maximum rate of increase in serum sodium concentration according to underlying cause of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) expressed in mEq/L/h and registered at either the first 8, 12, or 24 hours after tolvaptan administration. Dashed line denotes the maximum recommended rate of 0.5 mEq/L/h as reference. Abbreviation: CNS, central nervous system.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2018 National Kidney Foundation, Inc. Terms and Conditions

5. Figure 4
Representation of Spearman correlations between the magnitude of change in serum sodium concentration (in mEq/L) after 24 hours following tolvaptan therapy initiation and key baseline parameters in patients with syndrome of inappropriate secretion of antidiuretic hormone. Abbreviations: BMI, body mass index; Cr, creatinine; eGFR, estimated glomerular filtration rate; Osm, osmolality; SUN, serum urea nitrogen.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2018 National Kidney Foundation, Inc. Terms and Conditions

6. Figure 5
Representation of Spearman correlations between the magnitude of change in serum sodium concentration (in mEq/L) after 24 hours following initiation of tolvaptan therapy and key baseline parameters in patients with congestive heart failure. Abbreviations: BMI, body mass index; Cr, creatinine; Osm, osmolality; SUN, serum urea nitrogen.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2018 National Kidney Foundation, Inc. Terms and Conditions

7. Figure 6
Relationship between the magnitude of the initial 24-hour increase in serum sodium (sNa) concentration and baseline sNa concentration (in mEq/L) and serum urea nitrogen (SUN; in mg/dL) in the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) cohort (n=28). (A) The height of the bars represents the mixed-model-based–adjusted estimated mean 24-hour change in sNa concentration, and error bars reflect the standard error of the estimates. Changes were estimated at the 25th and 75th percentiles of baseline sNa (25th percentile = 118.5mEq/L, 75th percentile = 124.5mEq/L) and SUN concentrations (25th percentile = 6.0mg/dL, 75th percentile = 16.5mg/dL). (B) Baseline parameters were categorized according to the median as being higher or lower than the median (n=24, missing 24-hour sNa in 4 patients) and unadjusted values are displayed. P value for 2-way analysis of variance was < Posttest Tukey was performed to assess differences between groups; #P<0.05; ˆP<0.01; ∗P<
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2018 National Kidney Foundation, Inc. Terms and Conditions

8. Figure 7
Relationship between the magnitude of the initial 24-hour increase in serum sodium (sNa) concentration and baseline sNa values (in mEq/L) and serum urea nitrogen (SUN; in mg/dL) in the congestive heart failure (CHF) cohort (n=39). (A) The height of the bars represents the mixed-model–based adjusted estimated mean 24-hour change in sNa concentration, and error bars reflect the standard error of the estimates. Changes were estimated at the 25th and 75th percentiles of baseline sNa (25th percentile = 120mEq/L, 75th percentile = 124 mEq/L) and SUN concentrations (25th percentile = 14mg/dL, 75th percentile = 46mg/dL). (B) Baseline parameters were categorized according to the median as being higher or lower than the median (n=29, missing 24-hour sNa in 10 patients), and unadjusted values are displayed. P value for 2-way analysis of variance was <0.05. Posttest Tukey was performed to assess differences between groups. #P<0.05.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2018 National Kidney Foundation, Inc. Terms and Conditions